For more information on our recent data notice, please click here


State Stem Cell Agency Funds Three New UC San Diego Projects


August 25, 2021  |  

The governing Board of the California Institute for Regenerative Medicine (CIRM) has approved a trio of awards, totaling approximately $4 million, to University of California San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis (ALS).

The awards were announced August 24, 2021.

Building a better macrophage

Principal investigator Dan Kaufman, MD, PhD, professor of medicine in the Division of Regenerative Medicine and director of cell therapy at UC San Diego School of Medicine, and colleagues were awarded $1.4 million to develop a new chimeric antigen receptor (CAR-T) therapy for treating refractory or drug-resistant malignancies, such as ovarian cancer. The approach will used human induced pluripotent stem cells to engineer improved macrophages, ultimately resulting in a standardized, off-the-shelf therapy rather than current treatments that involve patient-specific development.

Improving stem cell migration

Principal investigator Ziwei Huang, PhD, professor in the Department of Medicine, and colleagues were awarded $1.1 million to develop a new therapeutic for directing the migration of target-specific therapeutic stem cells. The goal is to optimize treatment benefit by getting the stem cells to the disease site, specifically treatment of ALS.

Targeting cancer stem cells

Principal investigator Tannishtha Reya, PhD, professor of pharmacology and medicine, and colleagues were awarded $1.2 million to develop a small molecule inhibitor that blocks the growth of cancer stem cells that drive human pancreatic cancer and acute myeloid leukemia, leading to new treatments and improved diagnoses and prognoses.

CIRM was created by California voters in 2004 to fund stem cell research in the state, with the goal of accelerating treatments to patients with unmet medical needs. The agency funds research at institutions and companies throughout California. In 2020, California voters approved continued funding of CIRM.

Media Contact

Scott LaFee

Share This Article

Related News

UC San Diego Alpha Stem Cell Clinic awarded $8M to expand clinical trials of novel stem cell therapies. The CIRM award will advance partnerships between academic and industry experts in San Diego to e ...
Researchers discover that brain cancer tumors reprogram immune cells to help them grow, rather than suppress them.
UC San Diego researchers describe how the functional loss of a single gene negatively impacts neural development and promotes the growth of a particularly deadly form of pediatric brain cancer.
University of California San Diego School of Medicine researchers created a new type of brain cancer model for glioblastoma using stem cells, CRISPR and gene sequencing.

Follow Us